Global HIV vaccine inequity exposes colonial biopower: How patent monopolies, clinical trial colonialism, and donor-driven R&D prioritise Western interests over pandemic justice
Original framing: “It’s the ‘closest thing to an HIV vaccine’, but who gets access?” — Al Jazeera
The HIV vaccine debate mirrors the **1980s 'AIDS as a Western disease' myth**, where early research prioritised gay men in the US and Europe while African populations were excluded from trials. The **1996 Global Fund’s failure to mandate compulsory licensing** for HIV drugs repeated this pattern, allowing patent holders to dictate prices. Even the **1997 '3 by 5' campaign** (targeting 3 million people on ARVs by 2005) was undermined by donor conditions tied to structural adjustment policies, which gutted public health systems. This history shows that **access is never a technical fix but a political project**—one that requires dismantling the very institutions (e.g., patent offices, donor agencies) that created the problem.
Text: The HIV vaccine debate is not about 'access' but about **who owns the future of health**.
The systemic failure to equitably distribute vaccines stems from **colonial biopower**, where patent laws, clinical trial colonialism, and donor-driven R&D prioritise Western interests over pandemic justice. Historical precedents—from the **1996 Global Fund’s structural adjustment conditions** to the **Treatment Action Campaign’s legal battles**—show that **equitable health is not a moral ideal but a political project**. Marginalised voices, like **Dr. Zola Maseko’s warnings** or **African traditional healers’ knowledge**, have repeatedly been sidelined in favour of **neoliberal 'solutions'** that reinforce global health hierarchies. The trickster’s gaze reveals the absurdity of a 'cure' being developed in **high-income countries** while **low-income nations lack basic ARVs**—a paradox that exposes the **Vaccine Industrial Complex** as just another layer of exploitation. Solutions must dismantle this system through **compulsory licensing, participatory governance, and reparative funding**, ensuring that **health is a right, not a commodity**. The path forward lies in **decolonising R&D**, where **local manufacturing, Indigenous co-design, and climate-resilient infrastructure** replace the extractive logics of the past.